#ASCO24: Merck, Kelun trumpet Phase 3 breast cancer data for anti-TROP2 ADC
Merck and Kelun-Biotech revealed Phase 3 breast cancer data for the lead antibody-drug conjugate in their potentially $12 billion partnership. In a Phase 3 trial for locally recurrent or metastatic...
View ArticleClik here to view.
#ASCO24: J&J plans for capped, flexible dosing after four patient deaths in...
An experimental prostate cancer drug developed by Johnson & Johnson that uses a rare radioactive particle called actinium-225 led to three patients seeing their tumors shrink substantially, but...
View ArticleClik here to view.
Idorsia’s Jean-Paul Clozel retires as CEO, plots next steps; CRISPR...
Jean-Paul Clozel → Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether. Clozel will retire as CEO on June 13, and...
View ArticleClik here to view.
Zealand touts safety of new ‘double-G’ drug despite modest weight loss in...
Zealand Pharma appears to have taken a small step forward with a candidate that targets both GLP-1 and GLP-2, an approach that aims to ease side effects seen in many obesity drugs. In the...
View ArticleClik here to view.
Novo's semaglutide hits secondary endpoints in Ph3 kidney disease trial,...
Novo Nordisk’s semaglutide cut the risk of major cardiovascular events and death from multiple causes in a Phase 3 study involving patients with type 2 diabetes and chronic kidney disease, building the...
View ArticleHI-Bio outlines data that sparked $1.15B Biogen buyout
Days after getting acquired by Biogen, Human Immunology Biosciences revealed Phase 2 data that helped seal the deal. In the trial, which looked at the anti-CD38 antibody felzartamab’s potential to...
View Article#ASCO24: A roundup of the latest data from Merus, MorphoSys and others
Read on for news about Immunocore, Arcus, CG Oncology, Genmab, Merck and GSK: Merus stock spikes on data in head and neck squamous cell carcinoma: The biotech’s shares $MRUS rose more than 20% on...
View ArticleClik here to view.
Verastem's stock takes a hit after sharing updated filing plans in ovarian...
For a moment, Verastem Oncology looked like one of the early winners of the American Society of Clinical Oncology’s annual meeting. The company’s shares $VSTM were trading up over 50% after hours based...
View ArticleLilly budgets additional $5.3B for tirzepatide API factory in Indiana
Eli Lilly is further boosting manufacturing in its home state of Indiana. The company said it is allocating an additional $5.3 billion into its budget to build an active pharmaceutical ingredient (API)...
View ArticleFDA denies Ipsen's citizen petition for blockbuster drug Somatuline
US drug regulators have turned down Ipsen’s effort to slow down generic competition for its blockbuster drug Somatuline Depot, which is used to slow the growth of some tumors as well as for the rare...
View ArticlePublic Citizen sues FDA over citizen petition on SSRI sexual side effects...
The FDA should require drugmakers to warn patients of potential long-term sexual side effects from a certain class of antidepressants, the consumer advocacy group Public Citizen argued in a new lawsuit...
View ArticleStartup Hims has long-term plans for custom weight loss shots
Digital health company Hims & Hers plans to offer custom versions of wildly popular weight loss shots even after supply shortages resolve, according to an investor report this week. Hims’ stock...
View ArticleFDA advisory committee says risks of Novo Nordisk’s once-weekly insulin...
An FDA advisory committee on Friday voted not to recommend Novo Nordisk’s once-weekly insulin injection in type 1 diabetes patients. Novo has pitched its candidate as a more convenient alternative to...
View ArticlePfizer's $1.5B cuts; Biogen's $1.15B buyout; AstraZeneca's $80B ambition; RNA...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
Novartis to seek approvals in two rare kidney diseases after positive Phase 3...
Novartis is building out its rare kidney disease portfolio with two batches of Phase 3 data at the European Renal Association conference, touting positive results for an investigational drug in IgA...
View ArticleClik here to view.
After 14 years calling partnering shots at Genentech/Roche, James Sabry is...
Bioregnum Opinion Column by John Carroll James Sabry, the longtime doyen of biotech dealmakers from his global perch at Roche/Genentech, is jumping to the US biotech scene. The Basel-based pharma giant...
View ArticleBioNTech doubles down on ADC partner MediLink in new $1.8B biobucks pact
As BioNTech’s pipeline tilts back toward oncology, the German biotech is once again tapping a young Chinese partner in a bid for the next generation of the field’s hottest modality. It’s going back to...
View ArticleJapan’s Asahi Kasei offers to acquire Calliditas Therapeutics for $1B
A Japanese conglomerate is offering to buy Calliditas Therapeutics for more than $1 billion in a bid to enter a burgeoning autoimmune disease space. Three of Calliditas’ largest shareholders have...
View Article#ASCO24: Merus, touting more Phase 2 data, plots pivotal head and neck cancer...
Merus released additional head and neck cancer data from a Phase 2 study on Tuesday after publishing an ASCO abstract last week and outlined plans for a pivotal trial in the first-line setting. The...
View ArticleGilead forms pact with Cartography to map new targets for cancer drugs
Gilead will work with fellow California biotech Cartography Biosciences to find new targets for breast and lung cancer medicines, the companies said Tuesday morning. The deal includes $20 million...
View Article